Furthermore, the anti-HER inhibitor neratinib was administered to enhance the effectiveness of CDK4/6 inhibitor combined with endocrine therapy in HR+/HER2-low breast cancer by inhibiting the HER2 pathway and lowering HER2 mRNA expression. This evidence concerns the gene CDK4 and breast carcinoma.